In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1377-1384

  Schleiferböck, Sarah ^a,b   Scheurer, Christian ^a,b   Ihara, Masataka ^c,d   Itoh, Isamu ^c,d   Bathurst, Ian ^e   Burrows, Jeremy N ^e   Fantauzzi, Pascal ^e   Lotharius, Julie ^e   Charman, Susan A ^f   Morizzi, Julia ^f   Shackleford, David M ^f   White, Karen L ^f   Brun, Reto ^a,b   Wittlin, Sergio ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c HOSHI UNIVERSITY   (Japan)

^d Synstar Japan Co Ltd   (Japan)

^e Medicines for Malaria Venture   (Switzerland)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Antimalarial studies; Cross resistance; Plasmodium falciparum; Stage specificity

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; DRUG METABOLITE; MEFLOQUINE; PIPERAQUINE; PYRONARIDINE; SSJ 183; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; FEMALE; GENETIC STRAIN; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; SINGLE DRUG DOSE;

ANTIMALARIAL STUDIES; CROSS-RESISTANCE; PLASMODIUM FALCIPARUM; STAGE-SPECIFICITY;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HALF-LIFE; MALARIA; MICE; OXAZINES; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PYRIDINES;

EID: 84887722908     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S51298     Document Type: Article

References (17)

1. World Health Organization. World Malaria Report 2011. Summary and Keypoints. Available from: http://www.who.int/malaria/world_malaria_report_2011/wmr2011_summary_keypoints.pdf. Accessed September 8, 2012.
2. Olliaro PL, Taylor WR. Antimalarial compounds: from bench to bedside. J Exp Biol. 2003;206(Pt 21):3753-3759.
3. Ge J-F, Arai C, Yang M, et al. Discovery of novel benzo[a]phenoxazine SSJ-183 as a drug candidate for malaria. ACS Med Chem Lett. 2010; 1(7):360-364.
4. Lu J, Arai C, Md AB, Ihara M. Plasmodium berghei proteome changes in response to SSJ-183 treatment. Bioorg Med Chem. 2011;19(13): 4144-4147.
5. Burrows JN, Hooft van Huijsduijnen R, Möhrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.
6. Snyder C, Chollet J, Santo-Tomas J, et al. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp Parasitol. 2007;115(3):296-300.
7. Lambros C, Vanderberger JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65:418-420.
8. Hofer S, Brun R, Maerki S, Matile H, Scheurer C, Wittlin S. In vitro assessment of the pharmcodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum. J Antimicrob Chemother. 2008;62:1061-1064.
9. Maerki S, Brun R, Charman S, Dorn A, Matile H, Wittlin S. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. J Antimicrob Chemother. 2006;58:52-58.
10. Fivelman QL, Adagu IS, Warhurst DC. Fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48(11):4097-4102.
11. Charman SA, Arbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A. 2011;108(11):4400-4405.
12. Akoachere M, Buchholz K, Fischer E, et al. In vitro assessment of methylene blue on chloroquine-sensitive and-resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother. 2005;49(11):4592-4597.
13. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320(5874):330-334.
14. Saralamba S, Pan-Ngum W, Maude RJ, et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2011;108(1):397-402.
15. Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8(4): 272-280.
16. Witkowski B, Khim N, Chim P, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57(2):914-923.
17. Brunner R, Aissaoui H, Boss C, et al. Identification of a new chemical class of antimalarials. J Infect Dis. 2012;206(5):735-743.